Turn promising hits into optimized leads with integrated medicinal, synthetic, and computational chemistry.
Design-driven hit-to-lead and lead optimization guided by SAR.
Degrader and ADC design, from linker chemistry to payload.
Route scouting and scale-up that carry your series toward the clinic.
Complex synthesis and route design across novel chemical space.
Design and synthesis of peptides and peptidomimetics.
Robust, reproducible routes ready for GMP manufacturing.
AI-driven design, modeling, and virtual screening to focus effort.
Focused and diverse libraries to enrich your screening deck.
Discover and engineer better biologics from antibody campaigns through protein production and developability, with fully integrated discovery-stage science.
Campaigns across display and immunization to find binders that perform.
Engineer affinity, stability, and function into every candidate.
Conjugate design and optimization across linkers and payloads.
Expression and purification of research- to lead-grade protein.
Multispecific formats designed for developability and function.
Early liability screening to de-risk candidates before you commit.
Bridge molecule and disease with the assays, biomarkers, and models that build biological confidence before your program reaches the clinic.
Cloning, constructs, and cell engineering to enable your assays.
Mechanistic and binding assays that quantify how your molecule acts.
Phenotypic and target-based assays that model biology in the dish.
Functional readouts that connect target engagement to effect.
Identify and validate biomarkers that translate to the clinic.
In vitro and in vivo models built to reflect human disease.
Immune-focused assays and models for immuno-oncology and beyond.
Purpose-built oncology models and assays across tumor types.
CNS models and assays for neurodegeneration and neurobiology.
Understand how your compound behaves and where risk lives, with in vitro ADME, PK/PD, and GLP-ready toxicology built toward a confident IND.
Absorption, metabolism, and stability profiling to guide design.
In vivo pharmacokinetics across species to characterize exposure.
Validated LC-MS/MS and ligand-binding assays for every study.
Link exposure to effect to inform dose and design.
Early tox screening to surface liabilities before you commit.
GLP-compliant safety studies built toward a confident IND.
Board-certified pathology to interpret tissue-level findings.
Assess anti-drug antibody risk across biologics and modalities.
Core-battery safety assessment across vital organ systems.Focused and diverse libraries to enrich your screening deck.
Move from lab-scale to clinical supply with process, formulation, and GMP manufacturing designed to keep your timeline on track.
Stable, high-yield clones selected for productivity and quality.
Upstream and downstream processes optimized for scale.
Stable formulations that protect your molecule to the clinic.
Tech transfer and scale-up that hold quality as volume grows.
GMP supply of drug substance and product for clinical trials.
Antibody and protein manufacturing from cell line to fill.
Sterile fill-finish of clinical drug product.
Lyophilization cycle development for stability and shelf life.
E&L studies to ensure container and process safety.
Small molecule discovery and development chemistry, from hit to IND.
Bifunctional degraders that harness the ubiquitin-proteasome system.
Small molecules designed to selectively degrade target proteins.
Compounds that induce new protein-protein interactions.
Biologics discovery, development, and CDMO manufacturing solutions.
Single-target antibodies for precise, high-affinity binding.
Antibodies conjugated to cytotoxic or radioactive payloads.
Antibodies engineered to bind two distinct targets at once.
Peptide therapeutics and peptide-drug conjugate development.
mRNA and oligonucleotide therapeutics from design to scale-up.
Viral and non-viral vectors for in vivo and ex vivo gene delivery.
CAR-T and cell-based therapies from process to manufacturing.
Build confidence in CNS programs with neuroscience-specific biology, pharmacology, and models across neurodegeneration and neurobiology.
Cellular and molecular neuroscience to characterize target biology.
In vivo and in vitro pharmacology tailored to CNS targets.
Disease models spanning neurodegeneration and neurodevelopment.
Interrogate immune and inflammatory pathways with translational assays and models built to de-risk autoimmune and inflammatory targets.
Models spanning the major autoimmune indications and mechanisms.
Acute and chronic inflammation readouts across tissues and pathways.
Advance oncology and immuno-oncology programs with disease-relevant models spanning solid tumors, hematologic malignancies, and tumor immunity.
Cell-line and patient-derived models across major solid tumor types.
Models and assays for leukemia, lymphoma, and myeloma programs.
Assays that probe how the immune system engages the tumor.
Support metabolic and cardiometabolic programs with models that reflect the biology of obesity, diabetes, and related disease.
Models and endpoints for obesity, diabetes, and energy metabolism.
Assays bridging metabolic dysfunction and cardiovascular risk.
Advance cardiovascular programs with lipid and cardiovascular biology models built to translate to clinical endpoints.
Lipid and lipoprotein assays for dyslipidemia and related targets.
Cardiac and vascular models across major cardiovascular indications.
Target pathogens and the host response with anti-infective and host–pathogen models across bacterial, viral, and immune biology.
Discovery of biologics targeting bacterial and viral pathogens.
Assays mapping how pathogens and the immune system interact.
Chemistry-driven programs spanning hit discovery through IND filing.
Hit-to-lead chemistry advancing candidates to preclinical selection.
End-to-end chemistry support from candidate to IND submission.
In vitro and in vivo studies to characterize safety and exposure.
Process chemistry and manufacturing controls for scale-up readiness.
Regulatory strategy and filing support through every development stage.
Integrated biologics programs from antibody discovery to CDMO manufacturing.
Antibody discovery and engineering through IND-enabling studies.
Conjugation chemistry and process development for ADC candidates.
Contract research services spanning biologics discovery and testing.
Contract development and manufacturing for biologic therapeutics.
Seamless handoff from discovery through CMC development.
Real-world programs showcasing our discovery and development work.
Aberrant metabolism of cancer cells is well appreciated, but the identification of cancer subsets with specific metabolic vulnerabilities remains challenging.
Messenger RNA (mRNA) has emerged as a transformative technology for combating viral pandemics and malignancies, with lipid nanoparticle (LNP)-based mRNA vaccines playing a pivotal role in the COVID-19 pandemic.
Technical resources supporting your drug discovery and development.
In-depth technical papers on our discovery and development platforms.
Concise notes on methods, protocols, and technical best practices.
Peer-reviewed publications featuring our scientific research.
Perspectives and updates from our scientific and technical teams.
Perspectives and updates from our scientists and program teams.
Company announcements and the latest ChemPartner updates.
Webinars, conferences, and workshops from our global team.
Live and on-demand sessions covering key scientific topics.
Meet our team at major industry conferences worldwide.
Hands-on sessions exploring our discovery and development capabilities.
How ChemPartner grew into a global CRO/CDMO partner.
Meet the executives guiding our strategy.
Labs and offices across Asia, the US, and Europe.
Company news, milestones, and media coverage.
Strategic alliances that extend our discovery reach.
Financial reports and updates for our investors.
Our commitments to people, planet, and governance.
Explore open roles across our global teams.
Anti-hFc Capture
START YOUR JOURNEY